Biochemical and Pharmacological Effects of Chinese Medicines
on Homocysteine and Insulin-like Growth Factor-1 in Health and in Disease

CHUI Shiu Hon

A thesis submitted in partial fulfillment of the requirements

for the degree of

Doctor of Philosophy

Principal Supervisor: Prof. Kelvin K.C. CHAN

Hong Kong Baptist University

August 2004
ABSTRACT

The biochemical and pharmacological effects of a single Chinese medicinal (CM) herb, Danshen (丹参, Radix Salviae miltiorrhizae) and CM herbal formulae, VI-28 and Vittalliver suppositories on homocysteine or insulin-like growth factor 1 (IGF-1) were investigated at the cellular level, in healthy aging subjects and in patients with chronic liver diseases respectively.

Hyperhomocysteinemia increases oxidative stress, diminishes the vasodilation by nitric oxide, stimulates the proliferation of vascular smooth muscle cells and leads to oxidant injury to the endothelium. As a result, hyperhomocysteinemia is regarded as an independent risk factor for cardiovascular diseases, hypertension, stroke and dementia etc. The protective effect of Danshen extract against homocysteine-induced endothelial dysfunction using human umbilical vein endothelial cells (HUVECs) as a cell model was studied. Homocysteine (5 mmol/L) not only decreased cell viability but also caused disruption of capillary-like structure formation in vitro. The protective effect of Danshen aqueous extract and its active compounds on endothelial cell function was demonstrated through an in vitro tube formation assay using the HUVEC system. The active components in the aqueous extract of Danshen were characterized by HPLC. Danshen extract and its pure compounds showed different effectiveness in protecting HUVECs against homocysteine-induced injury in the following descending order: Danshen aqueous extract, Danshensu, protocatechuic acid, catechin and protocatechualdehyde.

With aging, there is a decline in growth hormone and IGF-1 and this contributes to altered metabolic changes and body composition in aging. In order to investigate whether the levels of homocysteine and/or IGF-1 would also be regulated by Chinese medicines, an exploratory 12 weeks open trial on VI-28, a Chinese herbal suppository formulated according to the anti-aging concept of traditional Chinese medicine, was conducted to examine its biochemical, immunological, hormonal and antioxidant effects on 31 healthy Chinese male subjects. Dose and time-dependent alterations in blood markers, such as HDL-cholesterol, cortisol, IGF-1, CD4 cell, RBC-CuZnSOD and plasma-DPPH scavenging equivalent were observed, with most of them showing beneficial changes after treatment.

The effects of VI-28 suppository on serum homocysteine and IGF-1 in 36 healthy Chinese males were studied over 16 weeks. IGF-1 levels of the whole cohort increased significantly during a 3-month treatment period, but no change was observed in serum homocysteine. However, when the cohort was divided into 2 groups using
homocysteine level of 13.0 µmol/L as the cut-off value that has been considered as getting towards hyperhomocysteinemia, a significant difference in IGF-1 was observed between the 2 groups at week 12. Furthermore, only the group with homocysteine level < 13.0 µmol/L showed significant elevation of IGF-1 throughout the 12 weeks of treatment with VI-283.

As the liver is the major organ for the metabolism of homocysteine and the production of IGF-1, the study on the effects of Chinese medicines on homocysteine and IGF-1 was extended to patients with chronic liver diseases (CLD), namely chronic hepatitis B (HBV) carriers with or without liver cirrhosis, using Vitalliver, a herbal suppository, similar but not identical to the VI-28 suppository in composition and function. Forty non-cirrhotic and 9 cirrhotic HBV carriers were treated with Vitalliver and observed for 3 months. Vitalliver reduced homocysteine levels in all 5 CLD patients with baseline homocysteine level > 13.0 µmol/L, and in 40 non-cirrhotic HBV carriers (changes dominated by 25 males) with mean homocysteine level < 13.0 µmol/L. Furthermore, Vitalliver was able to increase the IGF-1 levels of the non-cirrhotics with hepatitis B significantly at 1 month and 3 months after treatment, but those levels in the cirrhotics were not affected, despite the fact that the baseline IGF-1 levels of the cirrhotics were far lower than those of the non-cirrhotics. In addition, female non-cirrhotics had lower levels of homocysteine but higher levels of IGF-1 while the male patients showed the opposite pattern. This may confirm literature observations on lower levels of homocysteine in female population4.

The findings suggested that Chinese medicines, either a single herb (e.g. Danshen) or herbal formulae (e.g. VI-28 and Vitalliver) might produce beneficial effects on the regulation of homocysteine and/or IGF-1 either at the cellular level or in the systemic environment.

The present work has also illustrated that it is possible to carry out evidence-based research in general practice combining the expertise of Chinese medicine and the use of western medicine research methodologies and approaches in verifying the efficacy of Chinese medicine formulae. However, more studies will be needed to consolidate and substantiate the findings due to limitations such as the relatively small sample size of the study subject and not using a randomized, placebo-controlled approach when the work was conducted. Some future studies have been proposed towards such direction in the final chapter of the thesis.
Publications:

1. (1) Chui SH, Chan K, Wong RNS, Kong TK, Chen KJ. The inhibitory effect of homocysteine on the tube formation of endothelial cells can be reversed by the Danshen (Radix Salviae miltiorrhiza) extract. An abstract presented at the 2nd World Integrative Medicine Congress (2002) in Beijing (Appendix 1).

(2) Chan K, Chui SH, Wong DYL, Ha WY, Chan CL, Wong RNS. Protective effects of Danshensu from the aqueous extract of Salvia miltiorrhiza (Danshen) against homocysteine-induced endothelial dysfunction. Accepted for publication in Life Sciences.


presented at the International Conference & Exhibition of the Modernization of Chinese Medicine & Health Products (2003) in Hong Kong (Appendix 5).


(3) Chui SH, Chui AKK, Shek LSL, Wong RNS, Chan K. The effects of a Chinese medicinal suppository (Vitalliver) on insulin-like growth factor 1 and homocysteine in Chronic Hepatitis B carriers. Submitted for publication.
TABLE OF CONTENTS

DECLARATION i

ABSTRACT ii

ACKNOWLEDGEMENTS vi

TABLE OF CONTENTS viii

LIST OF TABLES xiii

LIST OF FIGURES xvi

LIST OF APPENDICES xx

LIST OF ABBREVIATIONS xxi

CHAPTER 1 INTRODUCTION 1

1.1 Homocysteine and its Biological Effects 2
   1.1.1 Metabolism of Homocysteine 2
   1.1.2 Hyperhomocysteinemia 4
       1.1.2.1 Causes of Hyperhomocysteinemia 5
       1.1.2.2 Effects of Hyperhomocysteinemia 9
   1.1.3 Clinical Significance of Hyperhomocysteinemia 10
   1.1.4 Changes of Homocysteine in Chronic Liver Diseases 12

1.2 Insulin-like Growth Factor 1 (IGF-1) 13
   1.2.1 IGF-1 - a Surrogate for Growth Hormone 13
   1.2.2 Changes of IGF-1 in Aging 14
   1.2.3 Changes of IGF-1 in Chronic Liver Diseases 15

1.3 The Biochemical Relationship between Homocysteine and IGF-1 16
CHAPTER 2 AIM AND DESIGN OF STUDY

2.1 Aim of Present Study

2.2 Study Design

2.3 Structure of the Thesis

CHAPTER 3 PROTECTIVE EFFECTS OF DANSHENSU FROM THE AQUEOUS EXTRACT OF RADIX SALVIAE MILTIORRHIZAE (DANSHEN) AGAINST HOMOCYSTEINE-INDUCED ENDOTHELIAL DYSFUNCTION

3.1 Materials and Methods

3.1.1 Materials

3.1.2 Methods

3.1.2.1 Cell Culture and Homocysteine Treatment

3.1.2.2 Assessment of Cell Viability

3.1.2.3 Tube Formation Assay

3.1.2.4 Purification and Characterization of Danshen Aqueous Extract and Danshensu

3.2 Results

3.2.1 Toxic Effect of Homocysteine on Cell Viability

3.2.2 Protective Effect of Danshen Aqueous Extract on HUVEC

3.2.3 Characterization of Danshen Aqueous Extract and Danshensu

3.2.4 Protective Effect of Different Active Compounds Against Homocysteine-induced Injury

3.3 Discussion
CHAPTER 4  BIOCHEMICAL, IMMUNOLOGICAL, HORMONAL AND ANTI-OXIDANT EFFECTS OF VI-28 ON ELDERLY

4.1 Materials and Methods

4.1.1 Materials
  4.1.1.1 Subjects
  4.1.1.2 Vigconic VI-28 Suppositories
  4.1.1.3 Serum Specimens for Laboratory Tests

4.1.2 Methods
  4.1.2.1 Treatment with VI-28
  4.1.2.2 Body Composition Analysis
  4.1.2.3 Laboratory Tests
  4.1.2.4 Statistical Analysis

4.2 Results

4.2.1 Clinical Observations
  4.2.1.1 Therapeutic Efficacy based on TCM Approach
  4.2.1.2 Assessments based on Clinical and Laboratory Approaches

4.2.2 Body Composition Analysis

4.2.3 Biochemical Effect

4.2.4 Immunological Effect

4.2.5 Hormonal Effect

4.2.6 Antioxidant Effect

4.3 Discussion

4.3.1 Body Composition Analysis

4.3.2 Serum Lipid Profile

4.3.3 Immune System

4.3.4 Hormones

4.3.5 Antioxidants

CHAPTER 5  EFFECTS OF VI-28 ON HOMOCYSTEINE AND IGF-1 IN HEALTHY MEN

5.1 Materials and Methods

5.1.1 Materials
5.1.1.1 Subjects 83
5.1.1.2 Vigconic VI-28 Suppositories 84
5.1.1.3 Specimens for Laboratory Tests 84

5.1.2 Methods 84
5.1.2.1 Study Design 84
5.1.2.2 Statistical Analysis 85

5.2 Results 85
5.2.1 Effects of Vigconic VI-28 on Serum Homocysteine, IGF-1 and IGFBP-3 85
5.2.2 Relationship between Homocysteine and IGF-1 86

5.3 Discussion 91

CHAPTER 6 EFFECTS OF VITALLIVER ON HOMOCYSTEINE AND IGF-1 IN CHRONIC LIVER DISEASES 96

6.1 Effects of Vitalliver on Homocysteine and IGF-1 in Chronic Hepatitis B Carriers without Liver Cirrhosis 98
6.1.1 Materials and Methods 98
6.1.1.1 Materials 98
6.1.1.2 Methods 101
6.1.2 Results 102
6.1.2.1 Changes of Homocysteine, IGF-1 and IGFBP-3 of the Whole Cohort 102
6.1.2.2 Changes of Homocysteine, IGF-1 and IGFBP-3 of Male Patients 103
6.1.2.3 Changes of Homocysteine, IGF-1 and IGFBP-3 of Female Patients 103
6.1.2.4 Comparison of Levels of Homocysteine, IGF-1 and IGFBP-3 between Male and Female Patients 104

6.2 Effects of Vitalliver on Homocysteine and IGF-1 in Chronic Hepatitis B Carriers with Liver Cirrhosis 111
6.2.1 Materials and Methods 111
6.2.1.1 Materials 111
6.2.1.2 Methods 113

6.2.2 Results 114

6.3 Comparison of Levels of Homocysteine, IGF-1 and IGFBP-3 between Non-cirrhotic and Cirrhotic HBV Carriers 114
6.3.1 Homocysteine 114
6.3.2 IGF-1 117
6.3.3 IGFBP-3 117

6.4 Discussion 121

CHAPTER 7 GENERAL DISCUSSION 128

CHAPTER 8 WORK TO BE DONE 135

REFERENCES 138

APPENDICES 167

CURRICULUM VITAE 189